<DOC>
	<DOCNO>NCT02257385</DOCNO>
	<brief_summary>This Phase IIIb multicentre , randomise , blind , triple dummy , parallel group study evaluate efficacy safety UMEC/VI inhalation powder ( 62.5/25 microgram [ mcg ] Once daily [ QD ] ) administer via ELLIPTA® Dry Powder Inhaler ( DPI ) compare indacaterol plus tiotropium ( 150 mcg/18 mcg respectively QD ) administer via individual inhaler treatment period 12 week participant moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) . The purpose study demonstrate UMEC/VI ( deliver via ELLIPTA DPI ) , use symptomatic moderate severe COPD participant , non-inferior combination indacaterol ( deliver via BREEZHALER® inhaler ) plus tiotropium ( deliver via HANDIHALER® inhaler ) measure trough force expiratory volume one second ( FEV1 ) 12 week treatment . Participants meet eligibility criterion screen ( Visit 1 ) complete 5 7 day run period prior randomisation Visit 2 . Clinic visit follow day 2 , week 2 , week 4 , week 8 week 12 treatment , plus week 12 + 1 day ( Visits 3 8 ) . The total duration study participation approximately 14 week . ELLIPTA register trademark GSK group company . HANDIHALER register trademark Boehringer Ingelheim Pharma GmbH &amp; Co. KG . BREEZHALER register trademark Novartis AG .</brief_summary>
	<brief_title>Comparative Study Umeclidinium/Vilanterol ( UMEC/VI ) Fixed Dose Combination With Indacaterol Plus Tiotropium</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Type subject : Outpatient Informed Consent : A sign date write informed consent prior study participation . Participants 40 year age old Visit 1 . Gender : Male female participant . A female eligible enter participate study : Nonchild bear potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy.OR Child bear potential , negative pregnancy test screening , agree one follow acceptable contraceptive method use consistently correctly ( i.e. , accordance approve product label instruction physician duration study screen followup contact ) : Abstinence , Oral Contraceptive , either combined progestogen alone , Injectable progestogen , Implants levonorgestrel , Estrogenic vaginal ring , Percutaneous contraceptive patch , Intrauterine device ( IUD ) intrauterine system ( IUS ) meet Standard Operating Procedure ( SOP ) effectiveness criterion state product label , Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject . For definition , `` document '' refers outcome investigator's/designee 's medical examination subject review subject 's medical history study eligibility , obtain via verbal interview subject subject ' medical record . Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society . Smoking History : Current former cigarette smoker history cigarette smoke &gt; =10 packyears . Former smoker define stop smoke least 6 month prior Visit 1 . Severity Disease : A pre postalbuterol/salbutamol Forced Expiratory Volume One Second/ Forced Vital Capacity ( FEV1/ FVC ) ratio &lt; 0.70 pre postalbuterol/salbutamol FEV1 &lt; =70 % predict normal value Visit 1 , calculate use Quanjer reference equation . Dyspnoea : A score &gt; = 2 Modified Medical Research Council Dyspnoea Scale ( mMRC ) Visit 1 . QT interval correct ( QTc ) Criteria : QTc &lt; 450 millisecond ( msec ) QTc &lt; 480 msec patient bundle branch block The QTc QT interval correct heart rate accord either Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , another method , machine manual overread . For subject eligibility withdrawal , QTcF use . For purpose data analysis , QTcF use primary . The QTc base single average QTc value triplicate Electrocardiogram ( ECGs ) obtain brief recording period . French participant : In France , subject eligible inclusion study either affiliate beneficiary social security category . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known alpha1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , opinion investigator , significant respiratory condition addition COPD exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Allergy rhinitis exclusionary . Other Diseases/Abnormalities : Participants historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 ( localize carcinoma skin resect cure exclusionary ) . Significant defined disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Contraindications : A history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , lactose/milk protein magnesium stearate medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician , contraindicate study participation use inhale anticholinergic beta 2 agonist . Hospitalisation : Hospitalisation COPD pneumonia within 12 week prior Visit 1 . Lung Resection : Participants lung volume reduction surgery within 12 month prior Screening ( Visit 1 ) . 12Lead ECG : An abnormal significant ECG find 12lead ECG conduct Visit 1 . Specific ECG finding preclude subject eligibility list protocol The study investigator determine medical significance ECG abnormality list . Screening lab : Significantly abnormal find clinical chemistry haematology test Visit 1 determine study investigator . Medication Prior Spirometry : Unable withhold albuterol/salbutamol 4 hour period require prior spirometry test study visit . Medications prior Screening : Use follow medication accord follow defined time interval prior Visit 1 : Depot corticosteroid ( 12 week ) ; Oral parenteral corticosteroid ( 6 week ) ; Antibiotics ( low respiratory tract infection ) ( 6 week ) ; Cytochrome P450 3A4 strong inhibitor ( 6 week ) ; Long Acting BetaAgonist ( LABA ) / inhaled corticosteroid ( ICS ) combination product ( e.g . fluticasone/salmeterol , mometasone , furoate/formoterol fumarate , budesonide/formoterol , fumarate ) , If LABA/ICS therapy discontinue completely ( 30 day ) ; If discontinue LABA therapy switch ICS monotherapy ( 48 hour salmeterol formoterol , 14 day Olodaterol , Indacaterol , Vilanterol ) ; Use ICS dose &gt; 1000 mcg/day fluticasone propionate equivalent ( 30 day ) ; Initiation discontinuation ICS use ( 30 day ) ; Inhaled long act beta2agonists ( LABA ) : Salmeterol , Formoterol ( 48 hour ) , Olodaterol , Indacaterol Vilanterol ( 14 day ) ; Long act muscarinic antagonist ( LAMA ) ( Tiotropium , Aclidinium , Glycopyrronium , Umeclidinium ) ( 7 day ) ; LABA/LAMA combination product ( Whichever mono component long washout ) ; Roflumilast ( 14 day ) ; Oral betaagonists Longacting ( 48 hour ) , Shortacting ( 12 hour ) ; Theophyllines ( 48 hour ) ; Oral leukotriene inhibitor ( zafirlukast , montelukast , zileuton ) ( 48 hour ) ; Inhaled sodium cromoglycate nedocromil sodium ( 24 hour ) ; Inhaled short act beta2agonists ( 4 hour ) ; Inhaled shortacting anticholinergic ( short act muscarinic antagonist [ SAMA ] ) product eg ipratropium ( 4 hour ) ; Inhaled shortacting anticholinergic/shortacting beta2agonist combination product ( SAMA/Short Acting beta2agonists [ SABA ] ) ( 4 hour ) ; Any investigational medication ( 30 day within 5 drug halflives ) Oxygen : Use Long Term Oxygen Therapy ( LTOT ) .This define oxygen therapy prescribe great 12 hour per day . As needed oxygen use ( i.e . &lt; =12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , albuterol/salbutamol ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 12 week prior Visit 1 . Participants maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member aforementioned involve study . Inability read : In opinion investigator , subject unable read and/or would able complete questionnaire . Participants prescreen screen failure rescreened .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>efficacy</keyword>
	<keyword>FEV1</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>non inferiority</keyword>
	<keyword>vilanterol</keyword>
	<keyword>COPD</keyword>
	<keyword>safety</keyword>
	<keyword>tiotropium</keyword>
	<keyword>umeclidinium bromide</keyword>
	<keyword>GSK573719</keyword>
</DOC>